The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Does bevacizumab increase the risk of venous thromboembolism? A cohort study.
A. A. Khorana
Consultant or Advisory Role - Roche/Genentech; Sanofi
Honoraria - Boehringer Ingelheim; Eisai; Ortho Biotech; Roche/Genentech; Sanofi
Research Funding - LEO Pharma; Ortho Biotech; Sanofi
G. C. Connolly
No relevant relationships to disclose
M. R. Dalal
Employment or Leadership Position - Sanofi
J. Lin
Consultant or Advisory Role - Sanofi
Stock Ownership - Sanofi
Research Funding - Sanofi